The European Association Of Urology-Prostate Cancer

The challenge of prostate cancer drug approval versus reimbursement

Here at the European Association of Urology (EAU) congress in Paris, there are some interesting debates amongst delegates attending the meeting regarding new therapies either recently – or about to be approved – for castrate-resistant prostate cancer (CRPC). For example: … Continue reading ? read more..

source:http://pharmastrategyblog.com

Cancer News-News Wires-Research

J&J unblind Zytiga phase 3 trial in pre-chemotherapy castrate-resistant prostate cancer

The big cancer news that hit the news wires this morning was not entirely surprising: “Janssen Research & Development, LLC today announced that it has unblinded the Phase 3 study of ZYTIGA (abiraterone acetate) plus prednisone for the treatment of … Continue reading ? read more..

source:http://pharmastrategyblog.com